Nirav R. Shah, M.D., M.P.H. Commissioner Sue Kelly Executive Deputy Commissioner

Update: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

NEW YORK state department of HEALTH

Effective January 30, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Focalin XR (15mg, 30mg and 45mg), Lovenox 30 mg/0.3 ml and 40 mg/0.4 ml prefilled syringes, Solaraze, Tobramycin solution for inhalation (TOBI), Trilipix and Trizivir will be added to the program.
- Nasacort AQ will be removed from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 1/17/14):				
Appolate	Ecclip VD/15mg	(2) (2)	Cariatana	

Accolate	Focalin XR(15mg,30mg,45mg)	Soriatane
Adderall & Adderall XR	Gabitril 2mg, 4mg	Symbyax
Alphagan P 0.15%	Hepsera	Tegretol suspension
Astelin	Kadian	Tegretol XR
Bactroban cream	Lidoderm	Temodar
Carbatrol	Lovenox (all strengths)	ТОВІ
Catapres-TTS	Marinol	Tobradex
Combivir	Niaspan	Toprol XL
Depakote sprinkle	Prandin	Tricor
Dovonex cream	Prevpac	Trileptal suspension
Diastat	Prograf	Trilipix
Diovan HCT	Pulmicort Respules	Trizivir
Duetact	Sanctura XR	Vancocin
Epivir	Singulair granules	Valtrex
Felbatol	Solaraze	Ziagen tablet

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.